A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer

Melissa LaBonte Wilson, Dongyun Yang, Peter Wilson, Wu Zhang, Yasir Nagarwala, Kevin Koch, Colleen Briner, Tomomi Kaneko, Sun-Young Rha, Oleg Gladkov, Susan Urba, Dina Sakaeva, Michael Pishvaian, Ruey-Kuen Hsieh, Wei-Ping Lee, Heinz-Josef Lenz

Research output: Contribution to journalArticle

2 Citations (Scopus)
243 Downloads (Pure)

Abstract

An exploratory phase II biomarker-embedded trial (LPT109747; NCT00526669) designed to determine the association of lapatinib-induced fluoropyrimidine gene changes with efficacy of lapatinib plus capecitabine as first-line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma independent of tumor HER2 status. Tumor biopsies obtained before and after 7-day lapatinib (1,250 mg) to analyze changes in gene expression, followed by a 14-day course of capecitabine (1,000 mg/m(2) twice daily, 14/21 days) plus lapatinib 1,250 mg daily. Blood samples were acquired for pharmacokinetic analysis. Primary clinical objectives were response rate (RR) and 5-month progression-free survival (PFS). Secondary objectives were overall survival (OS), PFS, time to response, duration of response, toxicity, and identification of associations between lapatinib pharmacokinetics and biomarker endpoints. Primary biomarker objectives were modulation of 5-FU-pathway genes by lapatinib, effects of germline SNPs on treatment outcome, and trough steady-state plasma lapatinib concentrations. Sixty-eight patients were enrolled; (75% gastric cancer, 25% gastroesophageal junction). Twelve patients (17.9%) had confirmed partial response, 31 (46.3%) had stable disease, and 16 (23.9%) had progressive disease. Median PFS and OS were 3.3 and 6.3 months, respectively. Frequent adverse events included diarrhea (45%), decreased appetite (39%), nausea (36%), and fatigue (36%). Lapatinib induced no changes in gene expression from baseline and no significant associations were found for SNPs analyzed. Elevated baseline HER3 mRNA expression was associated with a higher RR (33% vs. 0%; P = 0.008). Lapatinib plus capecitabine was well tolerated, demonstrating modest antitumor activity in patients with advanced gastric cancer. The association of elevated HER3 and RR warrants further investigation as an important player for HER-targeted regimens in combination with capecitabine
Original languageEnglish
JournalMolecular Cancer Therapeutics
Volume15
Issue number9
DOIs
Publication statusPublished - 01 Sep 2016

Fingerprint Dive into the research topics of 'A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer'. Together they form a unique fingerprint.

  • Cite this

    LaBonte Wilson, M., Yang, D., Wilson, P., Zhang, W., Nagarwala, Y., Koch, K., Briner, C., Kaneko, T., Rha, S-Y., Gladkov, O., Urba, S., Sakaeva, D., Pishvaian, M., Hsieh, R-K., Lee, W-P., & Lenz, H-J. (2016). A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. Molecular Cancer Therapeutics, 15(9). https://doi.org/10.1158/1535-7163.MCT-15-0908